Form 4 for BCTX BriaCell Therapeutics Corp.

Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-14 · accession 0001493152-24-020660 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2024-05-20	2024-05-14	BCTX	Lustig Marc	Dir, 10%	P - Purchase	$2.22	+902.9K	2.54M	+55%	+$2.00M
DI	2024-05-20	2024-05-14	BCTX	Lustig Marc	Dir, 10%	P - Purchase	—	+902.9K	902.9K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2024-05-14	P	A	902,935	$2.22	2,542,935	I By L5 Capital Inc.	—	—	(F1) The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.
2	Derivative	Common Stock Warrants	2024-05-14	P	A	902,935	—	902,935	I By L5 Capital Inc.	$2.11 · — to —	902,935 Common Stock	(F1) The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.